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Research Expression of human eukaryotic initiation factor 3f 
oscillates with cell cycle in A549 cells and is 
essential for cell viability
Ana E Higareda-Mendoza1 and Marco A Pardo-Galván*2
Abstract
Background: Transcriptional and postranslational regulation of the cell cycle has been widely studied. However, there 
is scarce knowledge concerning translational control of this process. Several mammalian eukaryotic initiation factors 
(eIFs) seem to be implicated in controlling cell proliferation. In this work, we investigated if the human eIF3f expression 
and function is cell cycle related.
Results: The human eIF3f expression has been found to be upregulated in growth-stimulated A549 cells and 
downregulated in G0. Western blot analysis and eIF3f promotor-luciferase fusions revealed that eIF3f expression peaks 
twice in the cell cycle: in the S and the M phases. Deregulation of eIF3f expression negatively affects cell viability and 
induces apoptosis.
Conclusions: The expression pattern of human eIF3f during the cell cycle confirms that this gene is cell division 
related. The fact that eIF3f expression peaks in two cell cycle phases raises the possibility that this gene may exert a 
differential function in the S and M phases. Our results strongly suggest that eIF3f is essential for cell proliferation.
Background
The initiation of translation in eukaryotes is a complex
and multi-step process involving many translation initia-
tion factors (eIFs). It is the rate-limiting and a major regu-
lation step of mRNA translation. Translation initiation
factor 3 (eIF3) is the largest of these factors and is
involved in a number of different aspects of the initiation
phase. eIF3 forms a stable complex with the 40S ribo-
somal subunit, which prevents premature association
with the 60S subunit, binds the ternary complex eIF2-
GTP-Met-tRNA to the 40S subunit [1] and promotes
mRNA binding through interactions with the eIF4G sub-
unit of the cap binding complex. Mammalian eIF3 has
been purified [2] and consists of at least 13 non-identical
subunits with molecular masses ranging from 35 to 170
kDa [3,4], but their individual functions have not been
determined. The eIF3 subunit composition varies accord-
ing to the organism, the simplest eIF3 subunit conforma-
tion (six subunits) [5], being identified in the budding
yeast  Saccharomyces cerevisiae, and the highest in
humans (thirteen subunits from eIF3a to eIF3m) [6]. It
has been shown that purified eIF3 complex from S. cere-
visiae containing five subunits (eIF3a, eIF3b, eIf3c, eIF3g
and eIF3i) can replace mammalian eIF3 in an in vitro
assay for initiation [7]. This indicates a strong conserva-
tion of function of these subunits in eukaryotes, which
form an active "core", with additional subunits that vary
according to the organism, which may or may not be
present in other eukaryotic eIF3s. For instance, eIF3j is
present in mammals and yeast, but is lacking in plants [5];
eIF3d, eIF3e, eIF3f and eIF3h are present in mammals,
plants and in the fission yeast Schizosaccharomyces
pombe, but is absent in S. cerevisiae. It is proposed that
distinct subclasses of eIF3 complexes, containing differ-
ent combinations of core and non-core subunits, may
regulate the translation of specific subsets of mRNAs [8];
as well as other suggested eIF3 activities [9].
eIF3f is a member of the Mov34 family. Members of
this family contain an Mpr1/Pad N-terminal (MPN)
motif and are involved in different cellular processes such
as translation, transcription and proteasome regulation
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[10]. Although the role of eIF3f in the eIF3 complex has
not been defined, shut-off experiments in Schizosaccha-
romyces pombe showed that in a long-term period, eIF3f
is essential for viability, and that depleting this gene
markedly decreases global protein synthesis [8]. It has
also been suggested that eIF3f might be involved in mus-
cle cell size [11]. In vitro studies using rabbit reticulocyte
translation system indicate that in mammalian cells eIF3f
is a negative regulator of translation [12,13]. Ectopic
expression of this gene inhibits translation and overall cell
protein synthesis in human A375 cells [13]. Shi et al. [13]
also report that eIF3f is downregulated in several human
tumours, and that its overexpression inhibited cell prolif-
eration in melanoma and pancreatic cancer cells, induc-
ing them to enter apoptosis.
Together, these previous findings suggest that eIF3f
may be involved in the regulation of cell growth and pro-
liferation. In the present study, we investigated the role of
human eIF3f in cell cycle control. We report that eIF3f
expression is related to A549 dividing cells and, that the
expression profile of eIF3f during cell cycle is biphasic
with one maximum expression peak in the early S phase
and a second during mitosis. We show that eIF3f is essen-
tial for cell proliferation and its absence induces the cell
to enter apoptosis.
Results
Human eIF3f expression is cell growth related
Modulation of serum concentration in cell culture media
is a method that has been widely used to study regulatory
mechanisms that control cell proliferation, which
depends on microenvironmental signals such as the con-
centration of growth factors [14]. To induce cells to enter
a non-dividing state (G0) by serum deprivation, A549
cells were grown according to Tzen et al. [14]. eIF3f pro-
tein abundance was determined by a Western blot experi-
ment using a rabbit anti-eIF3f polyclonal antibody.
Results are presented in Figure 1A (see additional file 1:
Original Western blots for the data used in Figure 1A). As
shown, eIF3f protein increased over two-fold in serum
stimulated cells when compared to G0 cells. To confirm
this data, G0 and serum stimulated cells were transiently
transfected with a plasmid containing a luciferase
reporter gene driven by the first kilobase of the human
active eIF3f promoter (see section below). Results of
three independent assays in serum-stimulated cells
showed that luciferase activity increased in the same
extent as that of the eIF3f protein when compared to G0
cells (Figure 1B). These results confirm that, in A549
cells, eIF3f expression is related to cell growth.
A second eIF3f copy is present in human chromosome 2 
and it is not transcriptionally active in A549 and 293-H 
human cells
Kojima and Okada [15] identified several potential 5'-
inverted retrocopies, including eIF3f, and suggest that
mRNA retrotransposition coupled with 5' inversion may
be a mechanism to generate new genes distinct from
parental genes. The human genome contains two com-
plete coding sequences for eIF3f: one is located at chro-
mosome 11 and contains 7 introns, and chromosome 2
contains a second intronless copy. There is a 97% identity
between both coding sequences, which makes it difficult
to differentiate between both putative mRNAs. Since the
presence or abundance of eIF3f protein is an important
parameter in the present study, we investigated which of
these (or both) sequences are transcriptionally active,
because of their probable contribution in overall eIF3f
protein content. One kilobase upstream of the putative
translation initiation site of each coding sequence was
fused to the promotorless luciferase gene of pGL3 vector.
A549 and 293-H cells were transfected with the above-
mentioned genetic constructs and with the empty vector
pGL3 as control, and luciferase activity was determined.
The results of this experiment, shown in Figure 2, clearly
demonstrate that the promoter of the chromosome 11
intron-containing eIF3f coding sequence is transcription-
ally active in both cell lines, and that the promoter of the
intronless coding sequence is not active in either one of
them. We consider this approach as being the most direct
method to determine promoter activity, since luciferase
Figure 1 Human eIF3f expression is cell growth related in A549 
cells. A) Western blot (WB) analysis of eIF3f expression in quiescent 
A549 cells (G0) and proliferating asynchronous cultures (A). Tubulin WB 
is shown to document equal protein loading. B) Promoter activity of 
the upstream sequences of eIF3f by promoter driven luciferase activity 
in quiescent A549 cells (G0) and proliferating asynchronous cultures 
(A). Luciferase activity with the empty vector pGL3 was below 10 RLU/
μg of protein. Data expressed as mean ± SE; * p < 0.01 with respect to 
G0, n ≥ 3.
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activity is highly sensitive and there is no endogenous
luciferase activity.
Human eIF3f expression oscillates during cell cycle
Once demonstrated that eIF3f expression is related to
proliferation in A549 cells, we investigated its expression
profile during the cell cycle. To evaluate eIF3f expression
during the cell division process, eIF3f mRNA and protein
abundance were determined at different cell cycle phases.
A549 cells were synchronized with hydroxyurea (HU).
eIF3f protein abundance for each sample was determined
by Western blotting (Figure 3A, B). As shown in Figure 3
(see additional file 2: Original Western blots for the data
used in Figure 3A, additional file 3: Original Western
blots for the data used in Figure 3B, and additional file 4:
Original Western blots for the Cyclin B1 data used in Fig-
ure 3B), eIF3f protein level peaks twice during the cell
cycle: in the early S phase, and in Mitosis. Furthermore,
eIF3f mRNA abundance during cell cycle progression was
also determined for each sample by Northern blotting
(Figure 3C, D) (see additional file 5: Original Northern
blots for the data used in Figure 3C, and additional file 6:
Original Northern blots for the data used in Figure 3D).
These mRNA results show a similar expression pattern as
in protein, peaking twice in the G2/M and G1/S transi-
tion cell cycle phases. To confirm these results, we evalu-
ated eIF3f gene expression measuring its promotor
activity in serum-starved G0 phase, with HU (S phase)
and with nocodazole (M phase) treated cells (Figure 4A).
Analysis of cell cycle distribution for each pharmacologi-
cal agent used to arrest cells in the different cycle states is
indicated in Figure 4B. Micrographs of mitotic and inter-
phase cells are also represented to clearly distinguish
between mitotic and non-mitotic cells using DAPI stain-
ing. Evidently, eIF3f promoter activity is upregulated dur-
ing both cell cycle phases. This result strongly supports
the possibility that the eIF3f function or functions are
related to cell division.
eIF3f overexpression affects cell viability in alveolar A549 
cancer cells and induces apoptosis
We investigated the effect of eIF3f overexpression on
alveolar adenocarcinoma cells, by transiently transfecting
A549 cells with pFH11S containing a complete eIF3f
cDNA, or with empty pMSG vector as control, and moni-
tored its effect on cell viability. eIF3f overexpression was
confirmed by Western blot analysis (Figure 5A) (see addi-
tional file 7: Original Western blots for the data used in
Figure 5A). Cells overexpressing eIF3f show reduced via-
bility (Figure 5B) (see additional file 8: Amplified micro-
graphs for the data used in Figure 5B) and induction of
apoptosis (Figure 5C).
Endogenous eIF3f silencing by antisense RNA or siRNA 
inhibits cell growth and induces apoptosis in A549 cancer 
cells
To determine if eIF3f has a role on cell viability, A549
cells were transiently transfected with pFH11A (anti-
sense), or with empty pMSG vector. eIF3f protein level
was reduced in the antisense transfected cells with
respect to the control as shown in (Figure 6A) (see addi-
tional file 9: Original Western blots for the data used in
F i g u r e  6 A  a n d  6 B ) .  T h e  s a m e  e f f e c t  w a s  o b s e r v e d  i n
siRNA treated cells (Figure 6B) (see additional file 10:
Amplified micrographs for the data used in Figure 6C).
Cell growth was monitored and, as shown, silencing eIF3f
either by antisense or by siRNA significantly decreased
cell viability (Figure 6C). Afterwards, using acridine
orange and ethidium bromide staining and fluorescence
microscopy, we investigated whether the decrease in cell
viability by silencing eIF3f is associated with increased
apoptosis. We observed significantly increased apoptosis
in cells transfected with antisense-eIF3f or siRNA-eIF3f
(Figure 6D). These results show that eIF3f silencing
affects cell viability and induces apoptosis in A549 cells.
Discussion
Proper execution of the cell cycle requires the expression
a n d  a c t i v a t i o n  o f  k e y  p r o t e i n s  a t  s p e c i f i c  t i m e s .  T r a n -
scriptional regulation and post-translational modifica-
tions, such as phosphorylation and proteolysis, are
important for cell-cycle progression and have been stud-
ied extensively. However, much less is known about cell-
Figure 2 Transcriptional activity of human eIF3f gene. Promoter 
activity of the upstream sequence of eIF3f copy in chromosomes 2 is 
transcriptionally inactive in both 293-H and A549 asynchronous cul-
tures, as exhibited by luciferase activity; in contrast, the eIF3f gene in 
chromosome 11 is active. Luciferase activity with the empty vector 
pGL3 was below 10 RLU/μg of protein. Data expressed as mean ± SE; * 
p < 0.01 with respect to control (pGL3), n ≥ 3.
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Figure 3 Human eIF3f expression profile in A549 cells throughout the cell cycle. A) Expression of eIF3f protein (relative intensity units normalized 
with tubulin, panel B of this Figure), and mitotic index (%, verified with Cyclin B1 expression shown in panel B of this Figure) in a 24 hour cell cycle in 
A549 cells after HU release (t = 0 h). B) WB analysis of eIF3f (top), tubulin (middle), and Cyclin B1 (bottom) along the 24 h cell cycle. All proteins visualized 
by their respective specific antibodies. Only some of the timepoints represented in panel A are shown in panel B. The same membrane was used for 
eIF3f and tubulin blots. A second membrane was used for Cyclin B1, where protein concentration load was verified by another tubulin blot (not 
shown). C) Expression of eIF3f mRNA (relative intensity units normalized with 28S ribosomal RNA), and mitotic index (%) in a 24 hour cell cycle in A549 
cells after HU release (t = 0 h). D) Northern blot analysis of eIF3f mRNA (top) and 28S ribosomal RNA (bottom) along the 24 h cell cycle. Only some of 
the timepoints represented in panel C are shown in panel D.
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Figure 4 Promoter activity of the upstream sequence of functional eIF3f in quiescent A549 cells (G0), M, G1, and S synchronous cultures. 
A) Cell cultures in G0, M or S were transiently transfected with the promoter plasmid constructs and harvested 48 (for M and S cells) or 54 (for G0 cells) 
hours after transfection for luciferase activity assays. For cells in G1, cell cultures were transiently transfected with the promoter plasmid constructs for 
20 hours, then arrested in M phase with nocodazole for 24 hours, and finally released from nocodazole to harvest cells 4 hours later for luciferase ac-
tivity assays in G1. Luciferase activity with the empty vector pGL3 was below 10 RLU/μg of protein. Data expressed as mean ± SE; * p < 0.01 with respect 
to control (pGL3), n ≥ 3. B) Cell cycle distribution for nocodazole, HU and serum deprivation after release from arrest in M, S and G0, respectively. Cells 
were stained with DAPI at different timepoints to assess mitotic index. Micrographs of mitotic and interphase A549 cells are shown (top) at a magni-
fication of 264×.
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Figure 5 Ectopic expression of human eIF3f in A549 cells. A) WB analysis of eIF3f expression in transfected pMSG (control) and pFH11S (ectopic 
expression) A549 cultures. Tubulin WB is shown to document equal protein loading. B) Difference in cell growth in control and overexpressed eIF3f 
cultures after 24 and 48 hours of transfection. Timepoint cero represents cells before transfection. Cells were stained with acridine orange and ethid-
ium bromide to visualize cell morphology and death by necrosis or apoptosis. Final magnification: 40×. C) Percent of apoptosis in control (water and 
pMSG) and overexpressed eIF3f (pFH11S) transfected cells, estimated from cell counts in microscopic fields similar to those shown in panel B. Data 
expressed as mean ± SE; * p < 0.01 with respect to control (water or pMSG), n ≥ 3.
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Figure 6 Expression silencing of human eIF3f in A549 cells. A) WB analysis of eIF3f expression in transfected pMSG (control) and pFH11A (anti-
sense) A549 cultures. Tubulin WB is shown to document equal protein loading. B) WB analysis of eIF3f expression in transfected scrambbled (control) 
and eIF3f siRNAs A549 cultures. Tubulin WB is shown to document equal protein loading. C) Difference in cell growth in control (water and scrambled 
siRNAs) and eIF3f siRNA treated A549 cultures after 24 and 48 hours of transfection. Left: suspended and adherent cells stained with trypan blue to 
assess cell viability after 24 hours of transfection. Right: Cells were stained with acridine orange and ethidium bromide to visualize cell morphology 
and death by necrosis or apoptosis. Timepoint cero represents cells before transfection. Final magnification: 40×. D) Percent of apoptosis in control 
(water and pMSG), antisense eIF3f (pFH11A), scrambled siRNAs and eIF3f siRNAs transfected cells, estimated from cell counts in microscopic fields sim-
ilar to those shown in panel C. Data expressed as mean ± SE; * p < 0.01 with respect to their respective control (water, scrambled siRNAs or pMSG), n 
≥ 3.
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cycle-specific translational control. Nevertheless, impor-
tant data has been obtained involving initiation of trans-
lation, the rate limiting step of the process, in the control
of cell proliferation. Expression of eIF4E is commonly ele-
vated in many human cancers and, frequently, it induces
cellular transformation, tumorigenesis and metastasis
[16,17] selectively enhancing the translation of mRNAs of
potent growth regulatory proteins such as Cyclin D [18].
Several investigations strongly suggest that eIF3 sub-
units are involved in cell cycle regulation [19]. For exam-
ple, elevated expression of eIF3a might be associated with
oncogenesis in some cancers, and it is possibly implicated
in regulating the expression of ribonucleotide reductase
[19] and p27 protein [20]. Downregulating the expression
of eIF3e by RNAi inhibited mitosis in HeLa cells [21].
Also, it has been reported that eIF3k binds to Cyclin D3, a
member of the Cyclin D family that mediates G1 phase
progression [22].
Although eIF3f has been implicated in cell proliferation
its role in this process has not been elucidated. In the
p r e s e n t  w o r k  w e  r e p o r t  t h a t  t h e  d e r e g u l a t i o n  o f  t h e
expression of eIF3f markedly affects cell proliferation.
eIF3f overexpressing in A549 cells show a significantly
increase in apoptosis compared to those transfected with
the vector alone (Figure 5). This result is in agreement
with that found in melanoma and pancreatic cancer cells
[13]. Downregulation of eIF3f expression by antisense-
eIF3f markedly increased apoptosis in A549 cells (Figure
6A). To confirm that result, we decided to transfect A549
cells with siRNA-eIF3f as a different and independent
experimental strategy. The results of this experiment
were similar to those obtained by antisense-eIF3f (Figure
6B). These results clearly show that eIF3f is essential for
the viability of A549 lung adenocarcinoma cells and that
silencing of this gene promotes apoptosis; in agreement
with this result, we found that downregulation of eIF3f
expression in plant cells also induced apoptosis (unpub-
lished data). Our data show that deregulation of eIF3f in
A549 cells induce apoptosis by means of a caspase-9
independent pathway (data not shown). Similarly, Shi et
al. [13] report that eIF3f overexpression in melanoma and
pancreatic cancer cells induce apoptosis through a cas-
pase-3 independent pathway. The fact that both knocking
down and ectopically overexpressing eIF3f suppressed
cell proliferation and induced apoptosis, suggests that
deregulation of eIF3f expression is not tolerated by the
cell. This may be explained by the specific expression
seen during cell cycle progression. Since the cell cycle
progression implies a coordinated and controlled series
of events, the increase or decrease in eIF3f expression
may affect the coordination of events specific to a cell
cycle phase, where it is needed as a negative regulator of
translation or required to be absent.
T o determine if eIF3f is associated to cell division, we
investigated weather there was a difference in eIF3f
expression between dividing and G0/G1 arrested cells. A
significantly decrease in eIF3f protein was found in G0
cells (Figure 1A), and this result was corroborated mea-
suring eIF3f-promotor activity (Figure 1B). Clearly, eIF3f
expression is associated with cell division. Recently, it was
r e p o r t e d  t h a t  e I F 3 a  e x p r e s s i o n  i s  c e l l  g r o w t h - r e l a t e d ,
unlike the core subunit eIF3b and the non-core subunit
eIF3d [23]. Interestingly, eIF3a expression increases dur-
ing growth in NIH3T cells, in a similar extent as does
eIF3f in A549 cells.
We investigated the relationship between eIF3f expres-
s i o n  a n d  c e l l  c y c l e  p r o g r e s s i o n .  W e  m e a s u r e d  h u m a n
eIF3f protein abundance and eIF3f promoter activity pro-
file through different cell cycle phases in synchronized
A549 cells, as shown in Figure 3. Surprisingly, eIF3f
expression oscillates during the cell cycle following a
biphasic profile, with one peak in the S phase and another
one in the M phase. Recently, it was shown that eIF3a
expression peaks in S phase in NIH3T cells [23]. Biphasic
translation at G1/S and G2/M is observed in ornithine
decarboxylase in HeLa cells [24]. In this case, ornithine
decarboxylase mRNA peaks only at G1/S, so at G2/M the
control of expression is exerted at the translational level.
In fission yeast (S. pombe) and plant cells (tobacco BY2
cell line), eIF3f expression peaks once during the cell
cycle in the G2 and M phases, respectively (unpublished
data), which suggests that the M phase expression peak in
human A549 cells represents the original eIF3f function
common to eukaryotes, and that the S phase peak in
human cells was later acquired. It remains to be eluci-
dated if eIF3f has the same function in both cell cycle
phases, as well as if other eIF3 subunits are growth and
cell cycle related in A549 cells and in other cell types. Sev-
eral studies show that eIF3f inhibits protein synthesis
[8,13]. Although the inhibitory effect of eIF3f on transla-
tion is robust, it is not a total protein synthesis inhibition:
it diminishes protein synthesis by 60-70%, remaining a
30-40%. Our interpretation is that eIF3f is not an inhibi-
tor, but a translational modulator that selects mRNAs at
specific cell cycle phase timepoints. This observation is
supported by previous studies where Arabidopsis thali-
ana translation initiation factor subunit eIF3h apparently
selects specific mRNAs through 5'mRNA leader
sequences [25], and S. pombe non-core subunits eIF3m
and eIF3e define distinct translation initiation factor 3
complexes, translating different sets of mRNAs [8]. Fan
and Penman [26] report that protein synthesis is greatly
inhibited in the G2/M and M phase in mammalian cells;
in this work we report that eIF3f is expressed in the M
phase of the cell cycle, so it is reasonable to suggest that
eIF3f contributes to this protein synthesis inhibition
observed in the M phase. We speculate that if eIF3f is aHigareda-Mendoza and Pardo-Galván Cell Division 2010, 5:10
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protein synthesis modulator, then mRNAs that should
not be translated during M cell cycle phase are selected
and transcribed during endogenous eIF3f knock down,
contributing to apoptosis induction.
Finally, the human genome contains two complete
eIF3f gene sequences, one with 7 introns and another one
with no introns. The human intron-containing sequence
has a similar genetic organization as that in most organ-
isms (data not shown), while the intronless one has char-
acteristics of a retrocopy [15,27]; both sequences having a
97% identity between them. Retroduplication is com-
monly thought to generate nonfunctional gene copies,
because they are expected to lack regulatory elements
that could promote retrocopy transcription. However,
different studies have shown that transcription of retro-
copies may not be rare [27-29]. Because there is a second
eIF3f expression peak in A549 cells, it was important to
know if one or both eIF3f copies were expressed. As Fig-
ure 2 shows, when two different human cell lines, A549
and 293-H, were transfected with either copy's promotor,
only that of the intron-containing copy of eIF3f was tran-
scriptionally active: thus, the intronless copy is most
likely a retropseudogene.
Conclusions
In this work we provide evidence that relates translation
with control of the cell cycle through eIF3f expression
and function. eIF3f function is related to the mitotic
phase in human A549 cells, and is essential for cell viabil-
ity. eIF3f abundance peaks in the S phase in human A549
cells and this increase seems not to be related to the pres-
ence of an intronless eIF3f copy, but to regulatory ele-
ments of the chromosome 11 eIF3f gene promoter.
Methods
Materials
Monoclonal antibodies against tubulin and caspase-9
were from Sigma Aldrich (ST . Louis, MO) and Upstate
(Lake Placid, NY), respectively. Rabbit polyclonal anti-
body against eIF3f was obtained from Global Peptide Ser-
vices, LLC (Fort Collins, CO) and later from Biolegend
(San Diego, CA). Mouse anti-Cyclin B1monoclonal anti-
body and horseradish peroxidase-conjugated anti-rabbit
and anti-mouse secondary antibodies were from Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). The pBlue-
script SK(-) vector is from Stratagene (La Jolla, CA). The
pGEM-T Easy and pGL3 basic plasmids, restriction
enzymes, DNA and RNA molecular weight markers, and
RNA polymerases were from Promega (Madison, WI).
The pMSG vector, GenomicPrep™ Cells and Tissue DNA
Isolation Kit, Protease Inhibitor Mix, protein molecular
weight markers, Hybond-P PVDF Membrane, Amersham
Hybond™-N+, and the Enhanced Chemiluminescence
(ECL) system for Western blot analysis were from GE
Healthcare Life Sciences (Piscataway, NJ). 293-H cell line,
293 SFM II medium, synthesized primers, the pSL301
vector, LipofectAMINE 2000, TRIzol®, and Quant-iT™
RiboGreen RNA Assay Kit were from Invitrogen (Carls-
bad, CA). DIG RNA Labeling Kit (SP6/T7), DIG Lumi-
nescent Detection Kit and Lumi-Film Chemiluminescent
Detection Film were from Roche (Indianapolis, IN). All
other reagents were of molecular biology grade and
obtained from Sigma Aldrich (Saint Louis, MO).
Cell culture
A549 cells, a human lung adenocarcinoma epithelial line,
were obtained from ATCC (designation CCL-185) and
used for all experiments. The cells were cultured in MEM
supplemented with 10% heat-inactivated fetal bovine
serum (FBS) at 37°C in a humidified atmosphere with 5%
CO2. A549 cells are adherent and grow with a doubling
time of approximately 22 hours. 293-H cells, clonal iso-
lates derived from transformed embryonal human kidney
cells, were cultured in suspension with 293 SFM II
medium supplemented with 2 mM L-glutamine at 37°C
in a humidified atmosphere with 8% CO2. A549 and 293-
H cells were routinely passaged twice per week to main-
tain them in a logarithmic growth phase.
Plasmid constructs
The pGL3 basic plasmid was used as the luciferase
reporter expression vector, where different fragments of
the human eIF3f promoter gene were introduced. Frag-
ments were amplified by PCR from A549 genomic DNA,
extracted with the GenomicPrep Kit. For the intron-con-
taining gene [Locus NP_003745], mapped on chromo-
some 11p15.4, we used the 11:7947867-11:7948866
fragment to generate a plasmid, called pF11P1K, that
encompasses 1 kb of genomic DNA corresponding to the
promoter (Forward Primer: ACATAGTGA-
TAAAAGCTTTGACTTAATAAC, Reverse Primer:
GCCGGTGTGGCAAGCTTGTCGAGAAAGAAGG).
For the intronless copy [NCBI removed record
XM_290345], mapped on chromosome 2p16.1, we used
the 2:58331072-2:58332078 fragment to generate a plas-
mid, called pF02P1K, that also encompasses 1 kb of
genomic DNA corresponding to the promoter region of
the eIF3f intronless copy (Forward Primer: TGTGGAG-
GATGTATTGAGCTAAAAC, Reverse Primer: TCTT-
GTCGAGATCTAGCTTTACTTTCAAAC). The pMSG
plasmid with the leaky inducible (dexamethasone)
MMTV LTR promoter was used to generate eIF3f gene
expression vector, called pFH11S, and eIF3f antisense
vector, called pFH11A. Total RNA was extracted from
A549 cells with TRIzol, according to the manufacturer's
instructions. eIF3f gene sequence [NCBI Entrez Gene
86652: Locus NP_003745] was amplified by RT-PCR
using forward primer TTCTCGACAAGATGGCCA-Higareda-Mendoza and Pardo-Galván Cell Division 2010, 5:10
http://www.celldiv.com/content/5/1/10
Page 10 of 13
CACCGGCG and reverse primer TCACAGGTTTA-
CAAGTTTTTCATTGAG. Amplification product was
subcloned in the pBluescript SK(-) vector (plasmid con-
struct pSK11F) and orientated into the pMSG plasmid to
generate the sense and antisense constructs. All con-
structs were verified by sequencing (Macrogen Corp,
Rockville, MD). The verified antisense targeting sequence
of eIF3f is 5'---ttctcgacaagATGgccacaccggcggtaccagtaagt
gctcctccggccacgccaaccccagtcccggcggcggccccagcctca
gttccagcgccaacgccagcaccggctgcggctccggttcccgctgcggctc
cagcctcatcctcagaccctgcggcagcagcggctg
caactgcggctcctggccagaccccggcctcagcgcaagctccagcgcaga
ccccagcgcccgctctgcctggtcctgctcttccagg
gcccttccccggcggccgcgtggtcaggctgcacccagtcattttggcctcca
ttgtggacagctacgagagacgcaacgagggtgct
gcccgagttatcgggaccctgttgggaactgtcgacaaacactcagtggagg
tcaccaattgcttttcagtgccgcacaatgagtcag
aagatgaagtggctgttgacatggaatttgctaagaatatgtatgaactgcata
aaaaagtttctccaaatgagctcatcctgggctg
gtacgctacgggccatgacatcacagagcactctgtgctgatccacgagtac
tacagccgagaggcccccaaccccatccacctcact
gtggacacaagtctccagaacggccgcatgagcatcaaagcctacgtcagc
actttaatgggagtccctgggaggaccatgggagtga
tgttcacgcctctgacagtgaaatacgcgtactacgacactgaacgcatcgg
agttgacctgatcatgaagacctgctttagccccaa
cagagtgattggactctcaagtgacttgcagcaagtaggaggggcatcagct
cgcatccaggatgccctgagtacagtgttgcaatat
gcagaggatgtactgtctggaaaggtgtcagctgacaatactgtgggccgctt
cctgatgagcctggttaaccaagtaccgaaaatag
ttcccgatgactttgagaccatgctcaacagcaacatcaatgaccttttgatgg
tgacctacctggccaacctcacacagtcacagat
tgcactcaatgaaaaacttgtaaacctgTGA---3'.
siRNA design and production
Design and production of siRNAs against eIF3f was car-
ried out according to Kittler et al. [30]. Briefly, eIF3f
sequence was analyzed in the DEQOR web-program [31]
to select a 400 to 600 bp sequence for the design and
quality control of siRNAs. The sequence from 529 to
1020 bp was amplified by PCR from the pFH11S vector
using forward primer CATGACATCACAGAGCAC and
reverse primer CAGGTAGGTCACCATCAA. The
siRNA targeting sequence of eIF3f is 5'---catgacatcacag
agcactctgtgctgatccacgagtactacagccgagaggcccccaaccccatcc
acctcactgtggacacaagt
ctccagaacggccgcatgagcatcaaagcctacgtcagcactttaatgggag
tccctgggaggaccatgggagtgatgttcacgcctct
gacagtgaaatacgcgtactacgacactgaacgcatcggagttgacctgatc
atgaagacctgctttagccccaacagagtgattggac
tctcaagtgacttgcagcaagtaggaggggcatcagctcgcatccaggatgc
cctgagtacagtgttgcaatatgcagaggatgtactg
tctggaaaggtgtcagctgacaatactgtgggccgcttcctgatgagcctggt
taaccaagtaccgaaaatagttcccgatgactttga
gaccatgctcaacagcaacatcaatgaccttttgatggtgacctacctg---3'.
The amplified sequence was cloned into the pGEM
plasmid to generate the pF11SIR vector. dsRNA were
obtained by in vitro transcription of the eIF3f fragment
s e q u e n c e  w i t h  T 7  a n d  T 3  R N A  p o l y m e r a s e s .  s i R N A s
against eIF3f were obtained by digestion of dsRNA with
RNase III, generating a mixture of siRNAs from 25 to 30
pb. Scrambled siRNAs were obtained by in vitro tran-
scription of the MCS of vector pSL301 with SP6 and T7
RNA polymerases and further digestion with RNase III.
siRNAs were cleaned with Q-sepharose columns.
Cell synchronization
Cells were accumulated in G0 by serum deprivation (0.1%
FBS) for 48 hours [14]. Synchronization and accumula-
tion of cells in M was achieved by adding 0.4 μg/mL of
nocodazole to the culture media [32]. Synchronization in
S phase was done by adding of 0.8 mM HU to the culture
media [33]. After 24 hours of synchronization with HU or
nocodazole, samples were processed to determine
parameters in S or M phase, respectively. For sample tak-
ing at specific timepoints, cells were washed 2 times with
phosphate-buffered saline (PBS, pH 7.4), another 2 times
with MEM and refed with fresh medium. Cells were
accumulated in G1 by releasing cells synchronized in M
for 24 hours, washing twice with PBS and MEM, adding
MEM and incubating for 4 hours. Cell synchrony was
m i c r o s c o p i c a l l y  ( L E I C A  D M  I L  F L U O ,  W e t z l a r ,  G e r -
many) assessed by determining the mitotic index on cells
fixed with 1% formaldehyde/0.2% glutaraldehyde for 5
min at room temperature [34], and stained with 4',6-
diamidino-2-phenylindole (DAPI). Each timepoint was
assessed in triplicate, and at least 400 cells were scored in
each sample. To confirm mitotic index, Cyclin B1 expres-
sion was determined by Western blot analysis at specific
timepoints: from serum-starved cells (Q: quiescence),
mitotic cells (M), proliferating asynchronous cells (A),
and serum stimulated cells at 0, 3, 5, 7, 9, 12, 15, 19, 22
and 24 hours after HU release [35-37].
Northern-blot analysis
Total RNA was extracted from A549 cells with TRIzol,
according to the manufacturer's instructions. The result-
ing RNA pellet was air-dried, resuspended in nuclease-
free water, and treated with amplification-grade DNase I.
RNA was quantified using a spectrophotometer (Jenway,
Burlington, NJ); A260/280 readings between 1.8 and 2.0
were used to ensure purity. T otal RNA was also quanti-
fied with a VersaFluor fluorometer (Bio-Rad, Hercules,
CA) using Quant-iT™ RiboGreen RNA Assay Kit, accord-
ing to the manufacturer's instructions. Agarose/formal-
dehyde denaturing gel electrophoresis, as described by
Sambrook and Russel [34], was performed with 10 μg of
total RNA, and intact 18S and 28S ribosomal RNA were
verified. To compare the RNA loaded in each lane, 28SHigareda-Mendoza and Pardo-Galván Cell Division 2010, 5:10
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ribosomal RNA was quantified and used to normalize
eIF3f mRNA data. For quantification purposes, 28S ribo-
somal RNA densitometric measurements were per-
formed using the Kodak Digital Science Electrophoresis
Documentation and Analysis System 100 for Windows
( R oc hest e r ,  NY) . An upwa r d ca pil la ry t ra ns f e r of  RNA
from the gel to a nylon membrane (Amersham Hybond™-
N+) [34] was performed, and RNA was fixed on the
membrane by baking 2 hours at 80°C. According to the
manufacturer's specifications, a complementary anti-
sense single-stranded RNA probe of eIF3f was produced
with the DIG RNA Labeling Kit (T7) using the plasmid
construct pSK11F as the template: eIF3f cDNA subcloned
in the pBluescript SK(-) vector in a antisense orientation
with respect to the T7 RNA polymerase site. Prehybrid-
ization, RNA:RNA hybridization and high stringency
post-hybridization washes of blots were performed
according to the DIG Application Manual for Filter
Hybridization (Roche). Hybridization bands were visual-
ized by DIG Luminescent Detection Kit using Lumi-Film
Chemiluminescent Detection Film.
Western-blot analysis
For Western blot analysis, cells were scraped from dishes
and cellular protein extracts were prepared by homogeni-
zation in ice cold lysis buffer (25 mM Tris pH 7.8, 15 mM
MgSO4, 4 mM EGTA, 1% Triton X-100 and 1 mM DTT)
containing a protease inhibitor mix. 15 μg of protein were
separated per lane by 10% SDS-PAGE gel electrophoresis.
After electrophoretic transfer of proteins to a polyvi-
nylidene difluoride (PVDF) membrane, eIF3f, Cyclin B1
or caspase-9 specific bands were detected by reaction
with a rabbit antibody against eIF3f, a mouse antibody
against caspase-9, followed by horseradish peroxidase-
conjugated anti-rabbit or anti-mouse secondary antibody,
respectively. Bands were visualized by enhanced chemilu-
minescence (ECL). Immunoblots were stripped using
mild antibody stripping solution and re-probed with a
mouse anti-tubulin antibody. For quantification pur-
poses, densitometric measurements were performed
using the Kodak Digital Science Electrophoresis Docu-
mentation and Analysis System 100 for Windows (Roch-
ester, NY). All eIF3f values were normalized to tubulin
levels.
Transient transfections
Transient transfections were performed using the cat-
ionic lipid, LipofectAMINE 2000, according to the manu-
facturer's specifications. All of these experiments were
performed in 6-well tissue culture plates with cells plated
to reach 60-70% confluence on the day of transfection.
Nucleic acid concentration for transfections with con-
structed and empty plasmids (vector control) was 2 μg,
and 3 μg for the siRNAs. Transfection times varied
according to each experiment. Cells were harvested 8, 24
and 48 hours after transient transfection with siRNAs,
eIF3f sense and antisense constructs, and control plas-
mids. For transfections with pMSG and derived con-
structs, 0.1 mM dexamethasone was added to the culture
medium. For luciferase activity assays with cells in G1,
cell cultures were transiently transfected with the pro-
moter plasmid constructs for 20 hours, then arrested in
M phase with nocodazole for 24 hours, and finally
released from nocodazole to harvest cells 4 hours later
(G1 cells). For luciferase activity assays with cells in M or
S, first cell cultures were transiently transfected with the
promoter plasmid constructs for 24 hours, then these
cultures were arrested with nocodazole or hydroxyurea
for 24 hours, to finally harvest transfected cells in M or S
phase, respectively. To determine luciferase activity in
G0, cell cultures were transiently transfected with the
promoter plasmid constructs for 6 hours, and then cul-
tures were accumulated in G0 by serum deprivation for
48 hours after which transfected cells were harvested for
luciferase activity assays.
Luciferase activity assay
Promoter activity was determined by measuring the
luciferase activities of cell lysates 48 hours after transfec-
tion with empty pGL3, pF11P1K or pF02P1K plasmids.
Briefly, cells were lysed in ice cold lysis buffer (25 mM
Tris pH 7.8, 15 mM MgSO4, 4 mM EGTA, 1% Triton X-
100 and 1 mM DTT). Each clarified cell lysate was first
assayed for total protein, using the Bio-Rad Protein Assay,
according to the manufacture's instructions (Bio-Rad,
Hercules, CA). After adjusting samples for equivalent
protein concentration in lysis buffer, samples were
assayed for luciferase activity as described by Sambrook
and Russel [34] with a Sirius Single Tube V3.1 Luminom-
eter (Berthhold, Huntsville, AL). Luciferase activity was
normalized to the respective total cellular protein.
Determination of cell viability
Adherent cells were released from the plate with Trypsin-
EDTA Solution (1×) and collected. Floating cells were
also recovered and included with the formerly adherent
cells for cell viability with the trypan blue exclusion
method. Percent of cell viability was determined micro-
scopically (LEICA DM IL, Wetzlar, Germany) by count-
ing triplicate samples of 200 to 400 cells in a
hemotocytometer chamber.
Determination of apoptosis and necrosis
Adherent cells were washed twice with PBS and stained
with a mixture of 4 μg/ml acridine orange and 4 μg/ml
ethidium bromide in PBS [38] for 5 minutes. Cells were
fixed with 1% formaldehyde/0.2% glutaraldehyde for 5
min at room temperature [34] and visualized by epifluo-Higareda-Mendoza and Pardo-Galván Cell Division 2010, 5:10
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resence microscopy (LEICA DM IL FLUO, Wetzlar, Ger-
many) at a magnification of 40×. Viable (normal, green
nuclei), early apoptotic (condensed, green nuclei), late
apoptotic (condensed, red nuclei), and necrotic (normal,
red nuclei) cells were counted. At least 400 cells were
scored in triplicate for each sample.
Statistical analysis
All experiments were repeated at least three times.
Results of multiple experiments are expressed as mean ±
standard error (SE). Analysis of Student's t test was used
to assess the differences between means. A P < 0.05, with
respect to control experiments, was accepted as statisti-
cally significant.
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Additional file 1 Original Western blots for the data used in Figure 1A. 
Original Western blots (WB) for the analysis of eIF3f expression in quiescent 
A549 cells (G0) and proliferating asynchronous cultures (A). The first WB 
(left) shows eIF3f expression, detected with a polyclonal rabbit anti-human 
eIF3f antibody (primary antibody) and HRP-conjugated goat anti-rabbit 
antibody (secondary antibody). To document equal protein loading, the 
second WB (right) shows tubulin expression, detected with a monoclonal 
mouse anti-human beta-tubulin antibody (primary antibody) and HRP-con-
jugated goat anti-mouse antibody (secondary antibody).
Additional file 2 Original Western blots for the data used in Figure 3A. 
Original Western blots (WB) for the analysis of eIF3f and tubulin expression 
in A549 synchronous cultures. The left WBs show eIF3f expression, detected 
with a polyclonal rabbit anti-human eIF3f antibody (primary antibody) and 
HRP-conjugated goat anti-rabbit antibody (secondary antibody). To docu-
ment equal protein loading, the WB at the right show tubulin expression, 
detected with a monoclonal mouse anti-human beta-tubulin antibody (pri-
mary antibody) and HRP-conjugated goat anti-mouse antibody (secondary 
antibody). Numbers represent the time in hours after HU release in A549 
cultures. (mw: protein molecular weight).
Additional file 3 Original Western blots for the eIF3f and tubulin data 
used in Figure 3B. Original Western blots (WB) for the analysis of eIF3f and 
tubulin expression in A549 synchronous cultures. The top WB shows eIF3f 
expression, detected with a polyclonal rabbit anti-human eIF3f antibody 
(primary antibody) and HRP-conjugated goat anti-rabbit antibody (second-
ary antibody). To document equal protein loading, the WB at the bottom 
shows tubulin expression, detected with a monoclonal mouse anti-human 
beta-tubulin antibody (primary antibody) and HRP-conjugated goat anti-
mouse antibody (secondary antibody). Numbers represent the time in 
hours after HU release in A549 cultures.
Additional file 4 Original Western blots for the Cyclin B1 data used in 
Figure 3B. Original Western blots (WB) for the analysis of Cyclin B1 expres-
sion in A549 synchronous cultures. The left WBs show Cyclin B1 expression, 
detected with a monoclonal mouse anti-Cyclin B1 antibody (primary anti-
body) and HRP-conjugated goat anti-mouse antibody (secondary anti-
body). To document equal protein loading, the WBs at the right show 
tubulin expression, detected with a monoclonal mouse anti-human beta-
tubulin antibody (primary antibody) and HRP-conjugated goat anti-mouse 
antibody (secondary antibody). Numbers represent the time in hours after 
HU release; M represents expression in mitotic A549 cells, by accumulating 
cells with nocodazole; A represents expression in A549 proliferating asyn-
chronous cultures; G0 represents expression in quiescent A549 cells, by 
accumulating cells with serum deprivation; and mw, protein molecular 
weight.
Additional file 5 Original Northern blots for the data used in Figure 
3C. A) Original Northern blots (NB) for the analysis of eIF3f mRNA expression 
in A549 synchronous cultures. The NBs show eIF3f mRNA expression, 
detected with a complementary antisense single-stranded RNA probe of 
human eIF3f. To document equal RNA loading and to normalize the expres-
sion of eIF3f mRNA, the relative intensity units of the 28S ribosomal RNA 
bands were determined. B) Total RNA gel photographs, corresponding to 
the NBs shown in panel A, and taken with a Hoefer Photoman Polaroid 
Camera (Hoefer Inc., Holliston, MA). Numbers represent the time in hours 
after HU release, and A represents expression in A549 proliferating asyn-
chronous cultures.
Additional file 6 Original Northern blots for the data used in Figure 
3D. Original Northern blot (NB) for the analysis of eIF3f mRNA expression in 
A549 synchronous cultures. The NB (top) shows eIF3f mRNA expression, 
detected with a complementary antisense single-stranded RNA probe of 
human eIF3f. To document equal RNA loading and to normalize the expres-
sion of eIF3f mRNA, the relative intensity units of the 28S ribosomal RNA 
bands were determined. Total RNA gel photograph (bottom) corresponds 
to the NB shown above, and taken with a Hoefer Photoman Polaroid Cam-
era (Hoefer Inc., Holliston, MA). Numbers represent the time in hours after 
HU release.
Additional file 7 Original Western blots for the data used in Figure 5A. 
Original Western blots (WB) for the analysis of eIF3f expression in A549 cul-
tures transfected with pMSG (control) and pFH11S (ectopic expression). 
A549 cells were lysed 48 hours after transfection and proteins were trans-
ferred to a PVDF membrane after separation by SDS-PAGE gel electrophore-
sis. The first WB (left) shows eIF3f expression, detected with a polyclonal 
rabbit anti-human eIF3f antibody (primary antibody) and HRP-conjugated 
goat anti-rabbit antibody (secondary antibody). To document equal protein 
loading, the second WB (right) shows tubulin expression, detected with a 
monoclonal mouse anti-human beta-tubulin antibody (primary antibody) 
and HRP-conjugated goat anti-mouse antibody (secondary antibody).
Additional file 8 Amplified micrographs for the data used in Figure 
5B. Amplified micrographs (~2 ×) of A549 cells transfected with pMSG (con-
trol) and pFH11S (ectopic expression). Micrographs were reduced to 40% of 
original size. Microscope final magnification: 40×.
Additional file 9 Original Western blots for the data used in Figure 
6Aand 6B. Original Western blots (WB) for the analysis of eIF3f expression in 
transfected A549 cultures with pMSG (control), pFH11A (antisense), scram-
bled siRNAs (control), and eIF3f siRNAs. A549 cells were lysed 48 hours after 
transfection and proteins were transferred to a PVDF membrane after sepa-
ration by SDS-PAGE gel electrophoresis. The first WB (left) shows eIF3f 
expression, detected with a polyclonal rabbit anti-human eIF3f antibody 
(primary antibody) and HRP-conjugated goat anti-rabbit antibody (second-
ary antibody). To document equal protein loading, the second WB (right) 
shows tubulin expression, detected with a monoclonal mouse anti-human 
beta-tubulin antibody (primary antibody) and HRP-conjugated goat anti-
mouse antibody (secondary antibody).
Additional file 10 Amplified micrographs for the data used in Figure 
6C. Amplified micrographs (~2 ×) of A549 cells transfected with scrambled 
siRNAs (control) and eIF3f siRNAs. Micrographs were reduced to 40% of 
original size. Microscope final magnification: 40×.Higareda-Mendoza and Pardo-Galván Cell Division 2010, 5:10
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